3 Biotech Stocks With Great Potential in 2014

These stocks had a great 2013 and may have an even better 2014.

Feb 11, 2014 at 2:30PM

Many large health care companies experienced a challenging fourth quarter and are reporting profits down versus the prior year, but biotechnology companies Vertex Pharmaceuticals (NASDAQ:VRTX), Alexion Pharmaceuticals (NASDAQ:ALXN), and Amgen (NASDAQ:AMGN) bucked the trend. All three have opportunities to expand their business in 2014.

Vertex swung to a fourth quarter profit from a loss in the fourth quarter of 2012 after receiving a royalty payout from former partner Johnson & Johnson for the overseas rights to its hepatitis C drug, Incivek. Incivek is one of only two approved drugs that Vertex currently has and came at an opportune moment, since U.S. domestic sales of the drug fell by more than 90% to $19 million. So, the royalty payment for overseas sales of the drug -- sold under the brand name Incivo by Johnson & Johnson outside of the U.S. -- made a huge impact on the results.

Overall, net income in the fourth quarter was $0.19 per share, which is a vast improvement on a loss of $0.35 per share in the fourth quarter of 2012. However, excluding the royalty payment and other one-time items, Vertex would have made a loss of more than $0.50 per share. So, while the earnings news is encouraging, it may be more difficult to duplicate since it was based on one-time items.

Still, shares in Vertex responded positively to the news and posted gains of more than 6% in the aftermath of the release. This week has seen shares lose much of that gain, but they remain more than 70% higher over the last year as the market responds relatively favorably to the measures introduced by Vertex to counter the challenges brought on by increased competition for Incivek, which included the loss of around 15% of its workforce.

Indeed, shares in Vertex have performed better than Alexion Pharmaceuticals, despite the latter posting gains of around 20% this week due to upbeat sales forecasts for Soliris. This is a treatment for a life-threatening condition called paroxysmal nocturnal hemoglobinuria, which causes a breakdown of red blood cells and leads to anemia.

Since its approval in 2007, Alexion has sought further marketing approvals to boost sales, and last month regulators deemed Soliris an orphan treatment for the prevention of delayed graft function, which is a complication for kidney-transplant patients. This, and other marketing approvals, have meant that the company's guidance for 2014 sales of the drugs are ahead of market forecasts, with shares reacting positively as a result.

Meanwhile, Amgenalso delivered impressive fourth quarter results, with total revenues increasing by 13% to $5 billion and product sales growing at 11%. Adjusted earnings per share increased by 30% to $1.82, with higher revenues, the end of the Enbrel profit share and a lower tax rate being offset (to an extent) by increased research and development spending.

Amgen appears to be well placed to deliver long-term growth, and shares are up 35% over the last year, surpassing gains on the Nasdaq, which is up around 27% over the same period. So, while many large health care stocks have disappointed recently, with fourth quarter results showing a decline in sales, the likes of Vertex, Amgen, and Alexion seem to have bucked the trend. Indeed, all three stocks have had a great 12 months and could be worth paying closer attention to over the course of 2014.

Vertex, Amgen, and Alexion have had a great run, but they may have trouble keeping up with this stock in 2014...
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens has no position in any stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals. It recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers